Announcements
Projects
Orgs
Project Post
Articles 15
Votes 0
The Pharma Letter
Articles
15
First pill for dengue - JNJ-1802 - shows promise - The Pharma Letter
>1y
A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost. British drugmaker GSK (LSE: GSK) has been working on the jab, dubbed M72, since it picked up rights to the candidate through its 2005 purchase of American biotech Corixa. While the vaccine has shown 54% effectiveness in a Phase II trial enrolling around ... - The Pharma Letter
~2y
Initial safety and immunogenicity results from a Phase III trial of Bavarian Nordic's (OMX: BAVA) chikungunya virus vaccine candidate have been announced. The candidate is known as PXVX0317. The company said that the study has already met its primary efficacy endpoints, with a strong induction of chikungunya virus neutralizing antibodies having been observed in 87% of those receiving the ... - The Pharma Letter
~2y
Pfizer and GSK to battle for share of new RSV vaccine market - The Pharma Letter
~2y
The UK Department of Health and Social Care (DHSC) proposes £39 million ($48.5 million) of funding for antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF). Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X – a global AMR research initiative – to support the continued early ... - The Pharma Letter
~2y
India's drug panel to review mRNA Omicron vaccine booster amidst COVID-19 surge - The Pharma Letter
>2y